Skip to content

Study · Animal study (in vivo) · mouse · 2016

7 results

ARA290, a Specific Agonist of Erythropoietin/CD131 Heteroreceptor, Improves Circulating Endothelial Progenitors' Angiogenic Potential and Homing Ability.

Hache G, Garrigue P, Bennis Y, Stalin J, Moyon A, Cerami A, Brines M, Blot-Chabaud M, Sabatier F, Dignat-George F, Guillet B

Shock (Augusta, Ga.)1 Oct 2016Cited by 18 (Europe PMC)

PMID27172159 (opens in a new tab)DOI10.1097/shk.0000000000000606 (opens in a new tab)PepBankPUB-27172159
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with chronic hindlimb ischemia given ECFC transplantation, a single ARA290 injection enhanced the ischemic/non-ischemic ratio of hindlimb blood flow after 28 days.

    In plain wordsIn mice with poor leg blood flow, one ARA290 injection plus cell transplant improved blood flow in the affected leg after 28 days.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseIschemic/non-ischemic hindlimb blood flow ratio at 28 days
    Study

    mousen: not reported in source

    chronic hindlimb ischemia with ECFC transplantation
    Outcome group
    Wound healing · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After ECFC transplantation to mice with CLI, a single ARA290 injection enhanced the ischemic/non-ischemic ratio of hindlimb blood flow and capillary density after 28 days and the homing of radiolabeled transplanted cells to the ischemic leg 4 h after transplantation.
    1 context sentence
    Summary · context
    We injected ARA290 to mice undergoing chronic hindlimb ischemia (CLI) in combination with ECFC transplantation.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with chronic hindlimb ischemia given ECFC transplantation, a single ARA290 injection enhanced capillary density after 28 days.

    In plain wordsIn mice with poor leg blood flow, one ARA290 injection plus cell transplant increased small blood vessel density after 28 days.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseCapillary density at 28 days
    Study

    mousen: not reported in source

    chronic hindlimb ischemia with ECFC transplantation
    Outcome group
    Wound healing · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After ECFC transplantation to mice with CLI, a single ARA290 injection enhanced the ischemic/non-ischemic ratio of hindlimb blood flow and capillary density after 28 days and the homing of radiolabeled transplanted cells to the ischemic leg 4 h after transplantation.
    1 context sentence
    Summary · context
    We injected ARA290 to mice undergoing chronic hindlimb ischemia (CLI) in combination with ECFC transplantation.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with chronic hindlimb ischemia, a single ARA290 injection enhanced the homing of radiolabeled transplanted cells to the ischemic leg 4 h after transplantation.

    In plain wordsIn mice with poor leg blood flow, one ARA290 injection helped transplanted cells reach the affected leg within 4 hours.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseHoming of transplanted ECFCs to ischemic leg 4 h after transplantation
    Study

    mousen: not reported in source

    chronic hindlimb ischemia with ECFC transplantation
    Outcome group
    Wound healing · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After ECFC transplantation to mice with CLI, a single ARA290 injection enhanced the ischemic/non-ischemic ratio of hindlimb blood flow and capillary density after 28 days and the homing of radiolabeled transplanted cells to the ischemic leg 4 h after transplantation.
    1 context sentence
    Summary · context
    The homing of transplanted ECFC to ischemic tissue in vivo was assessed by SPECT/CT imaging.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In mice with hindlimb ischemia, neutralizing CD31 on the transplanted cells before transplantation inhibited the ARA290-induced improvement of homing.

    In plain wordsIn mice, blocking the CD31 protein on transplanted cells stopped ARA290 from improving how well the cells reached the injured leg.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    Not applicableCD31 dependence of ARA290-induced homing
    Study

    mousen: not reported in source

    chronic hindlimb ischemia with ECFC transplantation
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Prior neutralization of platelet-endothelial cell adhesion molecule-1 (CD31) expressed by the transplanted cells inhibited ARA290-induced improvement of homing.
    1 context sentence
    Summary · context
    The homing of transplanted ECFC to ischemic tissue in vivo was assessed by SPECT/CT imaging.
  5. 05LabIn vitro (cells)Efficacy outcome

    In cultured endothelial colony-forming cells, ARA290 enhanced proliferation.

    In plain wordsIn lab tests on blood-vessel repair cells, ARA290 increased cell growth.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseECFC proliferation
    Study

    n: not reported in source

    endothelial colony-forming cells (ECFCs) in culture
    Outcome group
    Wound healing · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro, ARA290 enhanced the proliferation, migration, and resistance to H2O2-induced apoptosis of ECFCs.
    1 context sentence
    Summary · context
    ARA290 effects on ECFCs properties were studied using cell cultures in vitro.
  6. 06LabIn vitro (cells)Efficacy outcome

    In cultured endothelial colony-forming cells, ARA290 enhanced migration.

    In plain wordsIn lab tests on blood-vessel repair cells, ARA290 increased cell movement.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseECFC migration
    Study

    n: not reported in source

    endothelial colony-forming cells (ECFCs) in culture
    Outcome group
    Wound healing · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro, ARA290 enhanced the proliferation, migration, and resistance to H2O2-induced apoptosis of ECFCs.
    1 context sentence
    Summary · context
    ARA290 effects on ECFCs properties were studied using cell cultures in vitro.
  7. 07LabIn vitro (cells)Efficacy outcome

    In cultured endothelial colony-forming cells, ARA290 enhanced resistance to H2O2-induced apoptosis.

    In plain wordsIn lab tests on blood-vessel repair cells, ARA290 made the cells more resistant to programmed cell death caused by hydrogen peroxide.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseECFC resistance to H2O2-induced apoptosis
    Study

    n: not reported in source

    endothelial colony-forming cells (ECFCs) in culture
    Outcome group
    Wound healing · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro, ARA290 enhanced the proliferation, migration, and resistance to H2O2-induced apoptosis of ECFCs.
    1 context sentence
    Summary · context
    ARA290 effects on ECFCs properties were studied using cell cultures in vitro.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.